BRPI0511780A - tratamento com oxoliplatina e um inibidor de egrf - Google Patents

tratamento com oxoliplatina e um inibidor de egrf

Info

Publication number
BRPI0511780A
BRPI0511780A BRPI0511780-1A BRPI0511780A BRPI0511780A BR PI0511780 A BRPI0511780 A BR PI0511780A BR PI0511780 A BRPI0511780 A BR PI0511780A BR PI0511780 A BRPI0511780 A BR PI0511780A
Authority
BR
Brazil
Prior art keywords
treatment
oxoliplatin
kinase inhibitor
inhibitor
egfr
Prior art date
Application number
BRPI0511780-1A
Other languages
English (en)
Inventor
Jianping Chen
Brian Higgins
Kenneth Kolinsky
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34970379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0511780(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0511780A publication Critical patent/BRPI0511780A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

TRATAMENTO COM OXOLIPLATINA E UM INIBIDOR DE EGRF. A presente invenção refere-se a um método para a fabricação de um medicamento destinado ao tratamento de tumores ou metástases de tumor, caracterizado pelo fato de que uma quantidade terapeuticamente eficaz de um inibidor de cinase de EGFR e oxaliplatina é usado, com ou sem agentes ou tratamentos adicionais, tais como outros fármacos anticâncer ou terapias de radiação. A invenção também inclui uma composição farmacêutica que é constituída de uma combinação de inibidor de cinase de EGFR e oxaliplatina em combinação com um veículo farmaceuticamente aceitável. Um exemplo preferido de um inibidor de cinase de EGFR que pode ser usado na prática desta invenção é o composto erlotinib HCI (também conhecido como Tarceva<32>).
BRPI0511780-1A 2004-06-03 2005-05-25 tratamento com oxoliplatina e um inibidor de egrf BRPI0511780A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57643504P 2004-06-03 2004-06-03
PCT/EP2005/005638 WO2005117915A1 (en) 2004-06-03 2005-05-25 Treatment with oxaliplatin and an egfr-inhibitor

Publications (1)

Publication Number Publication Date
BRPI0511780A true BRPI0511780A (pt) 2008-01-15

Family

ID=34970379

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511780-1A BRPI0511780A (pt) 2004-06-03 2005-05-25 tratamento com oxoliplatina e um inibidor de egrf

Country Status (17)

Country Link
US (1) US20050272738A1 (pt)
EP (1) EP1755622A1 (pt)
JP (1) JP2008501650A (pt)
KR (1) KR100881043B1 (pt)
CN (1) CN1960737A (pt)
AR (1) AR049135A1 (pt)
AU (1) AU2005249200A1 (pt)
BR (1) BRPI0511780A (pt)
CA (1) CA2566974A1 (pt)
IL (1) IL179367A0 (pt)
MX (1) MXPA06013997A (pt)
NO (1) NO20066057L (pt)
NZ (1) NZ551354A (pt)
RU (1) RU2006146623A (pt)
TW (1) TW200608959A (pt)
WO (1) WO2005117915A1 (pt)
ZA (1) ZA200610050B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511800A (pt) * 2004-06-03 2008-01-15 Hoffmann La Roche tratamento com irinotecano (cpt-11) e um inibidor de egfr
WO2006081985A1 (en) * 2005-02-04 2006-08-10 F. Hoffmann-La Roche Ag Combined treatment with an n4-(substituted-oxycarbonyl)-5’-deoxy-5-fluorocytidine derivative and an epidermal growth factor receptor kinase inhibitor
UA98666C2 (ru) * 2010-03-25 2012-06-11 Геннадий Васильевич Мазильников Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения
UA98665C2 (ru) * 2010-03-25 2012-06-11 Геннадий Васильевич Мазильников Лекарственный препарат, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения
CN103339508A (zh) * 2010-12-09 2013-10-02 霍夫曼-拉罗奇有限公司 Agtr1作为贝伐单抗联合疗法的标志物
PL2890384T3 (pl) * 2012-08-31 2022-02-14 Taris Biomedical Llc Układy podawania leku i sposoby leczenia raka pęcherza obejmujące oksaliplatynę
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2042194A3 (en) * 1999-05-14 2009-04-22 Imclone Systems, Inc. Treatment of refractory human tumors with epidermal growth factor receptor antagonists
WO2000069915A2 (en) * 1999-05-17 2000-11-23 Avi Biopharma, Inc. COMBINED APPROACH TO TREATMENT OF CANCER WITH hCG VACCINES
US7049059B2 (en) * 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
KR20030068205A (ko) * 2001-01-09 2003-08-19 메르크 파텐트 게엠베하 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법
AU2004266572A1 (en) * 2003-08-01 2005-03-03 Wyeth Holdings Corporation Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
US20050250709A1 (en) * 2003-12-19 2005-11-10 Bionaut Pharmaceuticals Anti-neoplastic agents, combination therapies and related methods

Also Published As

Publication number Publication date
AR049135A1 (es) 2006-06-28
TW200608959A (en) 2006-03-16
CN1960737A (zh) 2007-05-09
KR100881043B1 (ko) 2009-01-30
US20050272738A1 (en) 2005-12-08
RU2006146623A (ru) 2008-07-20
AU2005249200A1 (en) 2005-12-15
EP1755622A1 (en) 2007-02-28
NO20066057L (no) 2007-02-28
WO2005117915A1 (en) 2005-12-15
IL179367A0 (en) 2007-03-08
ZA200610050B (en) 2008-08-27
NZ551354A (en) 2009-10-30
CA2566974A1 (en) 2005-12-15
JP2008501650A (ja) 2008-01-24
MXPA06013997A (es) 2007-02-08
KR20070029185A (ko) 2007-03-13

Similar Documents

Publication Publication Date Title
BRPI0511760A (pt) tratamento com gemcitabina e um inibidor de egfr
BRPI0510657A (pt) tratamento com cisplatina e com um inibidor de egfr
BRPI0517104A (pt) tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico
BR112023012301A2 (pt) Combinações farmacêuticas que compreendem um inibidor de kras g12c e usos de um inibidor de kras g12c para o tratamento de cânceres
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
WO2007075554A3 (en) Combination of igfr inhibitor and anti-cancer agent
BRPI0622054B8 (pt) composto e composição farmacêutica
EA200500893A1 (ru) Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR0116575A (pt) Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese
BR112014016163A2 (pt) piridoftalazinonas tetra ou penta-cíclicas fundidas como inibidores de parp
PT1951730E (pt) Derivados de pirimidina ligados a heteroalquilo
BRPI0417158A (pt) composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença
BR112022026186A2 (pt) Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras
BRPI0413745A (pt) horário mde dosagem para agentes anticancerìgenos erbb2
BRPI0517075A (pt) uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BRPI0511800A (pt) tratamento com irinotecano (cpt-11) e um inibidor de egfr
NO20044498L (no) Kombinasjonsterapi for behandling av cancer
BR112022026386A2 (pt) Inibidor de fgfr e mutação, método de preparação do mesmo e uso farmacêutico do mesmo
WO2009073139A3 (en) Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
TR200103418T2 (tr) Melatoninin tedavi edici kullanımı.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.